Figure 3.
Genomic aberrations in different tumor types. (A) Actionable variants in 20 CRC patients (n = number of patients) (left). Distribution of KRAS mutations that were detected in 11 (55%) CRC patients (right). (B) Actionable variants detected in 19 NSCLC patients (left). Distribution of KRAS mutations that were detected in six (31.6%) NSCLC patients (right). One NSCLC patient harbored two different KRAS mutations (p. G12C and p. A59G). (C) Actionable variants detected in 39 melanoma patients (left). Distribution of BRAF (right, top panel) and NRAS (right, bottom panel) mutations identified in 14 (35.9%) melanomas.